• IDA MUSFIROH Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia
  • GINNA MEGAWATI Department of Public Health, Division of Medical Nutrition, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia
  • DEWI MARHENI DIAH HERAWATI Department of Public Health, Division of Medical Nutrition, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia
  • AGUS RUSDIN Department of Pharmacy, Poltekkes Kemenkes Bandung, Bandung 40161, Indonesia




3d-Pharmacophore modelling, Omega-3 derivatives, PPAR-γ, and Obesity


Objective: The aim of this work was to study the pharmacophore model of omega-3 derivatives with the PPAR-γ receptor using LigandScout 4.4.3 to investigate the important chemical interactions of complex structure.

Methods: The methods consisted of structure preparation of nine chemical compounds derived from omega-3 fatty acids, database preparation, creating 3D Pharmacophore modelling, validation pharmacophore, and screening test compounds.

Results: The result of the research showed that the omega-3 derivatives docosahexaenoic acid (DHA), when eicosapentaenoic acid (HPA), and docosapentaenoic acid (DPA) have the best pharmacophore fit values of 36.59; 36.56; and 36.56, respectively. According to the results of the pharmacophore study, the carbonyl and hydroxyl of the carboxylate functional groups become the active functional groups that exhibit hydrogen bonding interactions. While the alkyl chain (Ethyl and methyl groups) was the portion that can be modified to increase its activity.

Conclusion: Omega-3 derivatives could be used as a lead drug for the powerful PPAR-γ receptor in the prevention and treatment of obesity.


Download data is not yet available.


Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4(2):113-9. doi: 10.1111/j.1559-4572.2008.00044.x, PMID 19614799.

Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98-107. doi: 10.1016/j.metabol.2018.10.011, PMID 30399375.

Morgan PJ, Young MD, Lloyd AB, Wang ML, Eather N, Miller A, Murtagh EM, Barnes AT, Pagoto SL. Involvement of fathers in pediatric obesity treatment and prevention trials: A systematic review. Pediatrics. 2017;139(2):1-18. doi: 10.1542/peds.2016-2635, PMID 28130430.

Calder PC. Very long-chain n-3 fatty acids and human health: fact, fiction and the future. Proc Nutr Soc. 2018;77(1):52-72. doi: 10.1017/S0029665117003950, PMID 29039280.

Senthil R, Sakthivel M, Usha S. Structure-based drug design of peroxisome proliferator-activated receptor-gamma inhibitors: ferulic acid and derivatives. J Biomol Struct Dyn. 2021;39(4):1295-311. doi: 10.1080/07391102.2020.1740790, PMID 32151198.

Wang Y, Yao Y, Liu J, Wu L, Liu T, Cui J, Lee DY. Synthesis and biological activity of piperine derivatives as potential PPARγ agonists. Drug Des Devel Ther. 2020;14:2069-78. doi: 10.2147/DDDT.S238245, PMID 32546971.

Megawati G, Herawati DMD, Musfiroh I. Binding affinity of omega 3 fatty acid an agonist PPAR-γ GPR120 receptor for obesity using molecular docking and ADME prediction. Eur J Mol Clin Med. 2021;7(10):1686-95.

Deckelbaum LI, Isner JM, Donaldson RF, Laliberte SM, Clarke RH, Salem DN. Use of pulsed energy delivery to minimize tissue injury resulting from carbon dioxide laser irradiation of cardiovascular tissues. J Am Coll Cardiol. 1986;7(4):898-908. doi: 10.1016/s0735-1097(86)80355-2, PMID 3082956.

Seidel T, Bryant SD, Ibis G, Poli G, Langer. 3D pharmacophore modeling techniques in computer-aided molecular design using LigandScout. Tutor Chemoinform. 2017;281:279-309.

Zou KH, O’Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115(5):654-7. doi: 10.1161/circulationaha.105.594929, PMID 17283280.

Caporuscio F, Tafi A. Pharmacophore modelling: a forty-year-old approach and its modern synergies. Curr Med Chem. 2011;18(17):2543-53. doi: 10.2174/092986711795933669, PMID 21568893.

Choudhury C, Narahari Sastry G. Pharmacophore modelling and screening: concepts, recent developments and applications in rational drug design. Challenges and Advances in Computational Chemistry and Physics; 2019. p. 25-53. doi: 10.1007/978-3-030-05282-9_2.

Voet A, Zhang KY. Pharmacophore modelling as a virtual screening tool for the discovery of small-molecule protein-protein interaction inhibitors. Curr Pharm Des. 2012;18(30):4586-98. doi: 10.2174/138161212802651616, PMID 22650262.

Kirchmair J, Distinto S, Markt P, Schuster D, Spitzer GM, Liedl KR, Wolber G. How to optimize shape-based virtual screening: choosing the right query and including chemical information. J Chem Inf Model. 2009;49(3):678-92. doi: 10.1021/ci8004226, PMID 19434901.

Seidel T, Ibis G, Bendix F, Wolber G. Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Technol. 2010;7(4):e221-8. doi: 10.1016/j.ddtec.2010.11.004.

Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Marki HP, Meyer M, Mohr P. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists. Bioorg Med Chem Lett. 2006;16(15):4016-20. doi: 10.1016/j.bmcl.2006.05.007, PMID 16737814.

Chang S, Jiao X, Li CH, Gong XQ, Chen WZ, Wang CX. Amino acid network and its scoring application in protein-protein docking. Biophys Chem. 2008;134(3):111-8. doi: 10.1016/ j.bpc.2007.12.005, PMID 18329160.



How to Cite

MUSFIROH, I., MEGAWATI, G., HERAWATI, D. M. D., & RUSDIN, A. (2021). 3D-PHARMACOPHORE MODELLING OF OMEGA-3 DERIVATIVES WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AS AN ANTI-OBESITY AGENT. International Journal of Applied Pharmaceutics, 13(4), 167–170. https://doi.org/10.22159/ijap.2021.v13s4.43851



Original Article(s)

Most read articles by the same author(s)

1 2 > >>